FDA s Mini-Sentinel Program Update for the Brookings Active Surveillance Implementation Council

Similar documents
FDA's Mini-Sentinel Program to Evaluate the Safety of Marketed Medical Products. Progress and Direction

Overview of FDA s Sentinel Initiative

Potential Steps in Active Surveillance

Evaluation of existing methods for safety signal identification for the Sentinel Initiative

Jeffrey Brown, PhD. November 12, 2013 Department of Population Medicine Harvard Pilgrim Health Care Institute/ Harvard Medical School

Large electronic healthcare databases for medical product safety surveillance The U.S. FDA Mini-Sentinel project

Overcoming Statistical Challenges to the Reuse of Data within the Mini-Sentinel Distributed Database

PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008

US FDA Sentinel Initiative

Pharmacovigilance & Signal Detection

Post-Marketing Surveillance Studies

Sentinel Journey from Safety Question to Regulatory Action. Rima Izem, PhD

S02: Presentations - Population Health Querying Electronic Health Data for Population Health Activities using PopMedNet TM

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency

Statistical Science at FDA

The Colorado Health Observation Regional Data Service (CHORDS): Creating a Shared Distributed Data Network for Local Public Health and Research Needs

Laboratory Tests Chronic Renal Deficiency (CRD) Patients (NCD )

Governing Interinstitutional

Innovative Uses of Electronic Databases for Enhanced Post-Market Safety

Surveillance Part 2. Marcia A. Testa, MPH, PhD Harvard School of Public Health

Vaccine Safety Monitoring, Reporting and Analysis. GBC 2017, Yun Chon, Ph. D

BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective

SYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier

Comparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data

IMEDS: Sentinel and OMOP Programs Jane Reese-Coulbourne, MS, ChE Executive Director Reagan-Udall Foundation for the FDA

USE OF PRIMARY CARE DATABASES IN EPIDEMIOLOGIC RESEARCH

Guidance for Industry, Review Staff, and the Clinical Community

So You Want to Develop a Test? Navigating the Regulatory Waters of Laboratory Developed Testing

Practice Guide APPLIED RESEARCH WORKS, INC.- COZEVA. 12/15/2016 v.2. Applied Research Works, Inc. 2016

The Future of Cancer and Public Health Surveillance A CDC perspective

UTILIZING REAL WORLD BIG DATA AND VISUAL ANALYTICS TO EXAMINE THE PATIENT JOURNEY

MEANINGFUL USE CRITERIA PHYSICIANS

These seminars are a collaborative work of NIATx, SAAS and The National Council supported by SAMHSA.

Guideline on good pharmacovigilance practices (GVP)

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

Unique Device Identification. Jay Crowley Senior Advisor for Patient Safety Food and Drug Administration

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach

Clinical Research and Adjudication

PCORI Methodology Standards: Academic Curriculum Patient-Centered Outcomes Research Institute. All Rights Reserved.

2016 Quality Measures Validation Audit Overview

The Changing Data Landscape in Alberta: Opportunities for Strengthening Analytics

Towards a Scalable Clinical Data Annotation and Processing Pipeline to Support Cancer Surveillance

Guideline on good pharmacovigilance practices (GVP)

SWOG

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

Regulatory Considerations and Evolving Issues Concerning REMS Programs

Improving Risk Management and Drug Safety. Janet Woodcock, MD Director Center for Drug Evaluation and Research U.S. Food and Drug Administration

Moving UDI from Regulation to Value Within Hospitals and Beyond

A Rapid-Learning Health System

Costs and Limitations. Medflow 2.0 EHR Release 10.1

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network

CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action

Framework for FDA s Real-World Evidence Program

Pharmacovigilance Practice in Pharmaceutical Industry. From Adverse Event Collection Risk Management

Understanding BPCI A For Skilled Nursing Facilities

Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA

Evolve or die: the urgent need to streamline randomized trials

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB

Distributed Health Data Networks: Implementing a Scalable Query Interface within PopMedNet for Use in Large-Scale Diverse Networks

FDA s Unique Device Identification Program

RE: FDA-2011-N-0090: Food and Drug Administration; Unique Device Identification System

Dr. Karen DeSalvo Office of the National Coordinator for Health Information Technology U.S. Department of Health and Human Services

Defining the true market

Brookings Roundtable on Active Medical Product Surveillance

MINI-SENTINEL METHODS PROPENSITY SCORE MATCHING TOOL ENHANCEMENTS REPORT

Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice. Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology

Powering the Connected Healthcare Ecosystem

DENOMINATOR: All final reports for patients, regardless of age, undergoing a CT procedure

Data Mining for Genomic- Phenomic Correlations

Pharmacogenomics within the EHR

May 21, Moderator: Rachael Fleurence, PhD NESTcc Executive Director

six years post six years post-- attestation

SHARED SERVICES: THE BENEFITS OF WORKING TOGETHER. Michigan Care Improvement Registry

EXAM COVER SHEET. Course Code: CLS 432. Course Description: Clinical Biochemistry. Example Past Exam Modal Answer.

Editor Guidelines. Ethics Approval and Informed Consent Statements

Distributed Data Analytics & Querying: EHR Value to Health Centers & Public Health

Cost-based, Value-based, and Reference-based Pricing for Diagnostics

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting

Data Collection Tools Functions, Indicators & Sub-Indicators

Regulatory Aspects of Pharmacovigilance

National External Quality Assurance Program Pakistan (NEQAPP) a milestone in proficiency testing in Pakistan

David Shulan, MS, MD, FAAAAI

Guiding Principles on the Sharing of Clinical Trial Data. DNDi POLICIES

AIM Statement on Vaccine Storage and Management

NESTcc Call for Concepts Public Webinar. Rachael L. Fleurence, PhD. NESTcc Executive Director January 4, 2018

Pharmacovigilance in Asia: The China Perspectives. Disclaimer

1.0 INTRODUCTION AND OVERVIEW

Brookings Roundtable Webinar: Highlights from the Observational Medical Outcomes Partnership (OMOP) Annual Symposium

Duane Steward, DVM, MSIE, PhD Nemours, Chief Computer Scientist for Clinical Informatics University Central Florida, Assistant Professor

Transformational Data-Driven Solutions for Healthcare

Renal Dialysis Services

Registry Assessment of Peripheral Interventional Devices (RAPID) Used to treat infrainguinal arterial occlusive disease

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

FDA s Unique Device Identification Program

PRODUCT UNDER TEST TEST EVENT RESULT. Quality Manual ISO Test Lab Test Report

PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM

Transcription:

info@mini-sentinel.org 4 FDA s Mini-Sentinel Program Update for the Brookings Active Surveillance Implementation Council Richard Platt, MD, MSc Harvard Pilgrim Health Care Institute and Harvard Medical School June 1, 2011

info@mini-sentinel.org 5 Stages of postmarket surveillance Signal Generation Signal Refinement Signal Evaluation Aim = Identify excess risk All (suspected and unanticipated) adverse events (AEs), all products Specific AE:product pairs of concern A highly suspected AE:product pair Approach Repeated monitoring of ~10 of AE:product pairs or one-time expedited analysis of a single pair Example Active surveillance in Mini-Sentinel and VSD using coded electronic health information

info@mini-sentinel.org 6 Stages of postmarket surveillance Signal Generation Signal Refinement Signal Evaluation Aim = Identify excess risk All (suspected and unanticipated) adverse events (AEs), all products Specific AE:product pairs of concern A highly suspected AE:product pair Approach Repeated monitoring of ~10 of AE:product pairs or one-time expedited analysis of a single pair Example Active surveillance in Mini-Sentinel and VSD using coded electronic health information

info@mini-sentinel.org 7 Sentinel prototype Develop a consortium of data partners and other content experts Develop policies and procedures Create a distributed data network with access to electronic health data and full text records Develop secure communications capability Evaluate extant methods in safety science Develop new epidemiological and statistical methods as needed Evaluate FDA-identified medical product-adverse event pairs of concern

Distributed data partners info@mini-sentinel.org 8

info@mini-sentinel.org 9 Additional partners Institute for Health

info@mini-sentinel.org 10 Governance principles/policies Public health practice, not research Minimize transfer of protected health information and proprietary data Public availability of work product Tools, methods, protocols, computer programs Findings Data partners participate voluntarily Maximize transparency Confidentiality Conflict of Interest for individuals

Mini-Sentinel distributed data network Operations Center FDA 2 1 Mini-Sentinel Portal 5 Data Partner Firewall / Policies Review & Run Query Review & Return Results 3 Local Datasets 4 Local Datasets Local Datasets Local Datasets 1- Query (an executable program) is submitted by Coordinating Center to the Portal 2- Data Partners retrieve the query 3- Data partners review query and perform analysis locally by executing the distributed program 4- Data partners review results 5- Data partners return results to the Portal info@mini-sentinel.org 11

FDA Mini-Sentinel Distributed Data Network Portal control Executable programs Menu driven queries Mini-Sentinel Secure Portal User Authentication Query Interfaces and Distribution Query Management & Results Viewer Data Partner Login, Settings & Auditing Mini-Sentinel Functions 1. Governance -- FDA -- Planning Board 2. Assignment of user rights -- Ops Center all rights -- FDA menu-driven queries 3. Data resources and formats -- Mini-Sentinel Common Data Model -- Creation of distributed dataset via programs from Ops Center 4. Analyses performed via programs distributed by the portal -- Data partners control execution 5. Communication -- FDA, Brookings, Mini-Sentinel website, investigators publications 1. Kaiser Permanente A KP N Cal D KP HI B KP S Cal E KP GA 2. Aetna 3. Fallon 4. Group Health 6. Health Partners 7. Henry Ford Hlth System 8. Humana 10. Marshfield Clinic 11. TN Medicaid (Vanderbilt) PopMedNet Services to Mini-Sentinel 1. Network creation and support 2. Documentation 3. Software development 4. Administrative leadership 5. Secure portals FISMA compliant* C KP NW F KP CO 5. Harvard Pilgrim 9. Lovelace Clinic 12.WellPoint (HealthCore) Mini-Sentinel Distributed Database Subnetwork 12 *Powered by PopMedNet; www.popmednet.org

Distributed data partners info@mini-sentinel.org 13

Yearly enrollments (71M unique enrollees) info@mini-sentinel.org 14

info@mini-sentinel.org 15 Duration of enrollment 3+ years:31% 5+ years:18%

info@mini-sentinel.org 16 Methods development Epidemiology methods Taxonomy of study designs for different purposes Literature review for algorithms to identify 20 outcomes using claims data Data access and validation Successful test of ability to retrieve hospital records, redact identifiers, adjudicate diagnosis Statistical methods Better adjustment for confounding Case based methods Regression methods for sequential analysis

info@mini-sentinel.org 17

info@mini-sentinel.org 18 Next steps active surveillance Drugs Implement active surveillance protocol for acute MI related to new oral hypoglycemics Evaluate new safety issues for older drugs Evaluate impact of regulatory actions, e.g., restricted distribution Vaccines (Post-licensure Rapid Immunization Safety Monitoring PRISM) Active surveillance of rotavirus vaccine and intussusception Active surveillance of human papilloma virus vaccine and venous thromboembolism

Next steps data and methods Data Quarterly updates of distributed data set Add blood pressure, height, weight, tobacco use Add selected laboratory test results Evaluate methods for obtaining EHR data Identify complementary immunization data sources Methods Link to state immunization registries and health plans Test anonymous linkage between data partners Assess comparability of Mini-Sentinel data to national data Develop additional statistical methods info@mini-sentinel.org 19

info@mini-sentinel.org 20 Laboratory tests Glucose Hemoglobin A1c Hemoglobin Creatinine International Normalized Ratio (INR) Alanine aminotransferase (ALT) Alkaline Phosphatase Total Bilirubin Lipase D-dimer Absolute Neutrophil Count (ANC)

info@mini-sentinel.org 21 Laboratory tests What s a glucose? Variable methods of lab data capture from different sites Test characteristics (source, measurement process, clinical circumstances) are rarely neatly abstracted into discrete columns Nature of the test needs to be deduced from the test name which is not always so obvious Serum glucose vs whole blood glucose, vs urine glucose, CSF glucose Fasting or non fasting? Part of a glucose challenge test or not?

info@mini-sentinel.org 22 serum glucose 602 hits!

info@mini-sentinel.org 23 Challenges Develop reliable approaches to different types of: Medical products Outcomes Patients Data that are new to safety science (EHRs, inpatient settings, laboratories, ) Make the system operational Need for timeliness in detection and followup Avoid false alarms

info@mini-sentinel.org 24 Avoiding false alarms Develop a framework for evaluation Based on experience of CDC Vaccine Safety Datalink Evaluate signals before dissemination Steps range from simple data checks to detailed epidemiologic evaluation. Examples: Search for data anomalies: errors, missing data, changes in coding practices Assess temporal/geographic clustering Evaluate additional control exposures/groups Confirm outcomes Search for confounders

February 10, 2011. Volume 364: 498-9 info@mini-sentinel.org 25

Thank you info@mini-sentinel.org 28